Document:

NEITHER
THIS SECURITY NOR THE SECURITIES AS TO WHICH THIS SECURITY MAY BE EXERCISED HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE
COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT
OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO,
THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A
LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY.
THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN
ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.

 

COMMON
STOCK PURCHASE WARRANT

 

TOUCHPOINT
GROUP HOLDINGS, INC.

 

Warrant
Shares: 100,000,000

Date
of Issuance: October 18, 2022 (“Issuance Date”)

 

This
COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received (in connection with the issuance
of the senior secured promissory note in the principal amount of $71,000.00 to the Holder (as defined below) of even date) (the
“Note”), Mast Hill Fund, L.P., a Delaware limited partnership (including any permitted and registered assigns, the
“Holder”), is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter
set forth, at any time on or after the date of issuance hereof, to purchase from TOUCHPOINT GROUP HOLDINGS, INC., a Delaware corporation
(the “Company”), 100,000,000 shares of Common Stock (the “Warrant Shares”) (whereby such
number may be adjusted from time to time pursuant to the terms and conditions of this Warrant) at the Exercise Price per share
then in effect. This Warrant is issued by the Company as of the date hereof in connection with that certain securities purchase
agreement dated October 18, 2022, by and among the Company and the Holder (the “Purchase Agreement”). For the
avoidance of doubt, this Warrant is referred to in the Purchase Agreement as the “Second Warrant”. This Warrant is
subject to cancellation pursuant to the terms of the Note.

 

Capitalized
terms used in this Warrant shall have the meanings set forth in the Purchase Agreement unless otherwise defined in the body of
this Warrant or in Section 12 below. For purposes of this Warrant, the term “Exercise Price” shall mean $0.0006, subject
to adjustment as provided herein (including but not limited to cashless exercise), and the term “Exercise Period”
shall mean the period commencing on the Trigger Date (as defined in this Warrant) and ending on 5:00 p.m. eastern standard time
on the date that is five (5) years after the Trigger Date.

 

1.           EXERCISE
OF WARRANT.

 

(a)            Mechanics
of Exercise. Subject to the terms and conditions hereof, the rights represented by this Warrant may be exercised in whole
or in part at any time or times during the Exercise Period by delivery of a written notice, in the form attached hereto as Exhibit
A (the “Exercise Notice”), of the Holder’s election to exercise this Warrant. The Holder shall
not be required to deliver the original Warrant in order to effect an exercise hereunder. Partial exercises of this
Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect
of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of
Warrant Shares purchased. On or before the second Trading Day (the “Warrant Share Delivery Date”)
following the date on which the Holder sent the Exercise Notice to the Company or the Company’s transfer agent, and
upon receipt by the Company of payment to the Company of an amount equal to the applicable Exercise Price multiplied by the
number of Warrant Shares as to which all or a portion of this Warrant is being exercised (the “Aggregate Exercise
Price” and together with the Exercise Notice, the “Exercise Delivery Documents”) in cash or by
wire transfer of immediately available funds (or by cashless exercise, in which case there shall be no Aggregate Exercise
Price provided), the Company shall (or direct its transfer agent to) issue and deliver by overnight courier to the address as
specified in the Exercise Notice, a certificate, registered in the Company’s share register in the name of the Holder
or its designee, for the number of shares of Common Stock to which the Holder is entitled pursuant to such exercise (or
deliver such shares of Common Stock in electronic format if requested by the Holder). Upon delivery of the Exercise Delivery
Documents, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares
with respect to which this Warrant has been exercised, irrespective of the date of delivery of the certificates evidencing
such Warrant Shares. If this Warrant is submitted in connection with any exercise and the number of Warrant
Shares represented by this Warrant submitted for exercise is greater than the number of Warrant Shares being acquired upon an
exercise, then the Company shall as soon as practicable and in no event later than three business days after any exercise and
at its own expense, issue a new Warrant (in accordance with Section 6) representing the right to purchase the number of
Warrant Shares purchasable immediately prior to such exercise under this Warrant, less the number of Warrant Shares with
respect to which this Warrant is exercised.

 

     1

     

    

 

If
the Company fails to cause its transfer agent to issue to the Holder the respective shares of Common Stock by the respective Warrant
Share Delivery Date, then the Holder will have the right to rescind such exercise in Holder’s sole discretion in addition
to all other rights and remedies at law, under this Warrant, or otherwise, and such failure shall also be deemed an event of default
under the Note, a material breach under this Warrant, and a material breach under the Purchase Agreement.

 

If
the Market Price of one share of Common Stock is greater than the Exercise Price, then the Holder may elect to receive Warrant
Shares pursuant to a cashless exercise, in lieu of a cash exercise, equal to the value of this Warrant determined in the manner
described below (or of any portion thereof remaining unexercised) by surrender of this Warrant and an Exercise Notice, in which
event the Company shall issue to Holder a number of Common Stock computed using the following formula:

 

X
= Y (A-B)

 

    A

 

	 	Where 	X = 	the number of Shares to be
    issued to Holder.

 

	 	Y = 	the number of Warrant Shares
    that the Holder elects to purchase under this Warrant (at the date of such calculation).

 

	 	A = 	the Market Price (at the
    date of such calculation).

 

	 	B = 	Exercise Price (as adjusted
    to the date of such calculation).

 

(b)
         No Fractional Shares. No fractional shares shall be issued upon the exercise of this Warrant as a consequence of any adjustment
pursuant hereto. All Warrant Shares (including fractions) issuable upon exercise of this Warrant may be aggregated for purposes
of determining whether the exercise would result in the issuance of any fractional share. If, after aggregation, the exercise
would result in the issuance of a fractional share, the Company shall, in lieu of issuance of any fractional share, pay the Holder
otherwise entitled to such fraction a sum in cash equal to the product resulting from multiplying the then-current fair market
value of a Warrant Share by such fraction.

 

     2

     

    

 

(c)             Holder’s
Exercise Limitations. Notwithstanding anything to the contrary contained herein, the Company shall not effect any
exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section
1 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable
Exercise Notice, the Holder (together with the Holder’s affiliates (the “Affiliates”), and any other
Persons acting as a group together with the Holder or any of the Holder’s Affiliates (such Persons, “Attribution
Parties”)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of
the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and Attribution Parties shall
include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination
is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the
remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution
Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company
(including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise
analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution
Parties. Except as set forth in the preceding sentence, for purposes of this Section 1(c), beneficial ownership shall be
calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it
being acknowledged by the Holder that the Holder is solely responsible for any schedules required to be filed in
accordance therewith. In addition, a determination as to any group status as contemplated above shall be determined in
accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this
Section 1(c), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding
shares of Common Stock as reflected in (A) the Company’s most recent periodic or annual report filed with the
Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by
the Company or the Company’s transfer agent setting forth the number of shares of Common Stock outstanding. Upon the
written or oral request of a Holder, the Company shall within two Trading Days confirm orally and in writing to the Holder
the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be
determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the
Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock
was reported. The “Beneficial Ownership Limitation” shall be 4.99% of the number of shares of the Common Stock
outstanding at the time of the respective calculation hereunder. The limitations contained in this paragraph shall apply to a
successor holder of this Warrant.

 

(d)           
Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise. In addition to any other rights available
to the Holder, if the Company fails to cause the Company’s transfer agent to transmit to the Holder the Warrant Shares in
accordance with the provisions of this Warrant (including but not limited to Section 1(a) above pursuant to an exercise on or
before the respective Warrant Share Delivery Date, and if after such date the Holder is required by its broker to purchase (in
an open market transaction or otherwise) or the Holder’s brokerage firm otherwise purchases, shares of Common Stock to deliver
in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a “Buy-In”),
then the Company shall (A) pay in cash to the Holder, within one (1) business day of Holder’s request, the amount, if any,
by which (x) the Holder’s total purchase price (including brokerage commissions, if any) for the shares of Common Stock
so purchased exceeds (y) the product of (1) the number of Warrant Shares that the Company was required to deliver to the Holder
in connection with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was
executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares
for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder within
one (1) business day of Holder’s request the number of shares of Common Stock that would have been issued had the Company
timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases, or effectuates a cashless
exercise hereunder for, Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise
of shares of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of
the immediately preceding sentence, the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company
written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence
of the amount of such loss. Nothing herein shall limit a Holder’s right to pursue any other remedies available to it hereunder,
at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the
Company’s failure to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms
hereof.

 

     3

     

    

 

2.          
ADJUSTMENTS. The Exercise Price and the number of Warrant Shares shall be adjusted from time to time as follows:

 

(a)            Distribution of Assets. If the Company shall declare or make any dividend or other distribution of its assets (or rights
to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including without limitation
any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate
rearrangement or other similar transaction) (a “Distribution”), at any time after the issuance of this Warrant,
then, in each such case:

 

(i)          
any Exercise Price in effect immediately prior to the close of business on the record date fixed for the determination of holders
of shares of Common Stock entitled to receive the Distribution shall be reduced, effective as of the close of business on such
record date, to a price determined by multiplying such Exercise Price by a fraction (i) the numerator of which shall be the Closing
Sale Price of the shares of Common Stock on the Trading Day immediately preceding such record date minus the value of the Distribution
(as determined in good faith by the Company’s Board of Directors) applicable to one share of Common Stock, and (ii) the
denominator of which shall be the Closing Sale Price of the shares of Common Stock on the Trading Day immediately preceding such
record date; and

 

(ii)        
the number of Warrant Shares shall be increased to a number of shares equal to the number of shares of Common Stock obtainable
immediately prior to the close of business on the record date fixed for the determination of holders of shares of Common Stock
entitled to receive the Distribution multiplied by the reciprocal of the fraction set forth in the immediately preceding clause
(i); provided, however, that in the event that the Distribution is of shares of common stock of a company (other than the Company)
whose common stock is traded on a national securities exchange or a national automated quotation system (“Other Shares
of Common Stock”), then the Holder may elect to receive a warrant to purchase Other Shares of Common Stock in lieu of
an increase in the number of Warrant Shares, the terms of which shall be identical to those of this Warrant, except that such
warrant shall be exercisable into the number of shares of Other Shares of Common Stock that would have been payable to the Holder
pursuant to the Distribution had the Holder exercised this Warrant immediately prior to such record date and with an aggregate
exercise price equal to the product of the amount by which the exercise price of this Warrant was decreased with respect to the
Distribution pursuant to the terms of the immediately preceding clause (i) and the number of Warrant Shares calculated in accordance
with the first part of this clause (ii).

 

     4

     

    

 

(b)           
Anti-Dilution Adjustments to Exercise Price. If the Company or any Subsidiary thereof, as applicable, at any time while
this Warrant is outstanding, shall sell or grant any option to purchase, or sell or grant any right to reprice, or otherwise dispose
of or issue (or announce any offer, sale, grant or any option to purchase or other disposition) any Common Stock or securities
(including but not limited to Common Stock Equivalents) entitling any person or entity (for purposes of clarification, including
but not limited to the Holder pursuant to (i) any other security of the Company currently held by Holder, (ii) any other security
of the Company issued to Holder on or after the Issuance Date (including but not limited to the Note), or (iii) any other agreement
entered into between the Company and Holder) to acquire shares of Common Stock (upon conversion, exercise or otherwise), at an
effective price per share less than the then Exercise Price (such lower price, the “Base Share Price” and such issuances
collectively, a “Dilutive Issuance”) (if the holder of the Common Stock or Common Stock Equivalents so issued shall
at any time, whether by operation of purchase price adjustments, elimination of an applicable floor price for any reason in the
future (including but not limited to the passage of time or satisfaction of certain condition(s)), reset provisions, floating
conversion, exercise or exchange prices or otherwise, or due to warrants, options or rights per share which are issued in connection
with such issuance, be entitled or potentially entitled to receive shares of Common Stock at an effective price per share which
is less than the Exercise Price at any time while such Common Stock or Common Stock Equivalents are in existence, such issuance
shall be deemed to have occurred for less than the Exercise Price on such date of the Dilutive Issuance (regardless of whether
the Common Stock or Common Stock Equivalents are (i) subsequently redeemed or retired by the Company after the date of the Dilutive
Issuance or (ii) actually converted or exercised at such Base Share Price), then the Exercise Price shall be reduced at the option
of the Holder and only reduced to equal the Base Share Price, and the number of Warrant Shares issuable hereunder shall be increased
such that the aggregate Exercise Price payable hereunder, after taking into account the decrease in the Exercise Price, shall
be equal to the aggregate Exercise Price prior to such adjustment (for the avoidance of doubt, the aggregate Exercise Price prior
to such adjustment is calculated as follows: the total number of Warrant Shares issuable upon exercise of this Warrant immediately
prior to such adjustment (without regard to the Beneficial Ownership Limitation) multiplied by the Exercise Price in effect immediately
prior to such adjustment). By way of example, if E is the total number of Warrant Shares issuable upon exercise of this Warrant
immediately prior to such adjustment (without regard to the Beneficial Ownership Limitation), F is the Exercise Price in effect
immediately prior to such adjustment, and G is the Base Share Price, the adjustment to the number of Warrant Shares can be expressed
in the following formula: Total number of Warrant Shares after such Dilutive Issuance = the number obtained from dividing [E x
F] by G. Such adjustment shall be made whenever such Common Stock or Common Stock Equivalents are issued, regardless of whether
the Common Stock or Common Stock Equivalents are (i) subsequently redeemed or retired by the Company after the date of the Dilutive
Issuance or (ii) actually converted or exercised at such Base Share Price by the holder thereof (for the avoidance of doubt, the
Holder may utilize the Base Share Price even if the Company did not actually issue shares of its common stock at the Base Share
Price under the respective Common stock Equivalents). The Company shall notify the Holder in writing, no later than the Trading
Day following the issuance of any Common Stock or Common Stock Equivalents subject to this Section 2(b), indicating therein the
applicable issuance price, or applicable reset price, exchange price, conversion price and other pricing terms (such notice the
“Dilutive Issuance Notice”). For purposes of clarification, regardless of whether (i) the Company provides a Dilutive
Issuance Notice pursuant to this Section 2(b) upon the occurrence of any Dilutive Issuance or (ii) the Holder accurately refers
to the Base Share Price in the Exercise Notice, the Holder is entitled to receive a number of Warrant Shares based upon the Base
Share Price as well as the Base Share Price at all times on and after the date of such Dilutive Issuance.

 

(c)            Subdivision or Combination of Common Stock. If the Company at any time on or after the Issuance Date subdivides (by any
stock split, stock dividend, recapitalization or otherwise) one or more classes of its outstanding shares of Common Stock into
a greater number of shares, the Exercise Price in effect immediately prior to such subdivision will be proportionately reduced
and the number of Warrant Shares will be proportionately increased. If the Company at any time on or after the Issuance Date combines
(by combination, reverse stock split or otherwise) one or more classes of its outstanding shares of Common Stock into a smaller
number of shares, the Exercise Price in effect immediately prior to such combination will be proportionately increased and the
number of Warrant Shares will be proportionately decreased. Any adjustment under this Section 2(c) shall become effective at the
close of business on the date the subdivision or combination becomes effective. Each such adjustment of the Exercise Price shall
be calculated to the nearest one-hundredth of a cent. Such adjustment shall be made successively whenever any event covered by
this Section 2(c) shall occur.

 

3.            FUNDAMENTAL
TRANSACTIONS. If, at any time while this Warrant is outstanding, (i) the Company effects any merger of the Company with
or into another entity and the Company is not the surviving entity (such surviving entity, the
“Successor Entity”), (ii) the Company effects any sale of all or substantially all of its assets in one or
a series of related transactions, (iii) any tender offer or exchange offer (whether by the Company or by another individual
or entity, and approved by the Company) is completed pursuant to which holders of Common Stock are permitted to tender or
exchange their shares of Common Stock for other securities, cash or property and the holders of at least 50% of the Common
Stock accept such offer, or (iv) the Company effects any reclassification of the Common Stock or any compulsory share
exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property
(other than as a result of a subdivision or combination of shares of Common Stock) (in any such case, a “Fundamental
Transaction”), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive the
number of shares of Common Stock of the Successor Entity or of the Company and any additional consideration (the
“Alternate Consideration”) receivable upon or as a result of such reorganization, reclassification,
merger, consolidation or disposition of assets by a holder of the number of shares of Common Stock for which this Warrant is
exercisable immediately prior to such event (disregarding any limitation on exercise contained herein solely for the purpose
of such determination). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately
adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one
share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate
Consideration in a reasonable manner reflecting the relative value of any different components of the
Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be
received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it
receives upon any exercise of this Warrant following such Fundamental Transaction. To the extent necessary to effectuate the
foregoing provisions, any Successor Entity in such Fundamental Transaction shall issue to the Holder a new warrant consistent
with the foregoing provisions and evidencing the Holder’s right to exercise such warrant into Alternate
Consideration.

 

     5

     

    

 

4.           NON-CIRCUMVENTION. The Company covenants and agrees that it will not, by amendment of its certificate of incorporation,
bylaws or through any reorganization, transfer of assets, consolidation, merger, scheme of arrangement, dissolution, issue or
sale of securities, or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of
this Warrant, and will at all times in good faith carry out all the provisions of this Warrant and take all action as may be required
to protect the rights of the Holder. Without limiting the generality of the foregoing, the Company (i) shall not increase the
par value of any shares of Common Stock receivable upon the exercise of this Warrant above the Exercise Price then in effect,
(ii) shall take all such actions as may be necessary or appropriate in order that the Company may validly and legally issue fully
paid and non-assessable shares of Common Stock upon the exercise of this Warrant, and (iii) shall, for so long as this Warrant
is outstanding, have authorized and reserved, free from preemptive rights, two (2) times the number of shares of Common Stock
into which the Warrants are then exercisable into to provide for the exercise of the rights represented by this Warrant (without
regard to any limitations on exercise).

 

5.           WARRANT HOLDER NOT DEEMED A STOCKHOLDER. Except as otherwise specifically provided herein, this Warrant, in and of itself,
shall not entitle the Holder to any voting rights or other rights as a stockholder of the Company. In addition, nothing contained
in this Warrant shall be construed as imposing any liabilities on the Holder to purchase any securities (upon exercise of this
Warrant or otherwise) or as a stockholder of the Company, whether such liabilities are asserted by the Company or by creditors
of the Company.

 

6.           REISSUANCE.

 

(a)            Lost, Stolen or Mutilated Warrant. If this Warrant is lost, stolen, mutilated or destroyed, the Company will, on such terms
as to indemnity or otherwise as it may reasonably impose (which shall, in the case of a mutilated Warrant, include the surrender
thereof), issue a new Warrant of like denomination and tenor as this Warrant so lost, stolen, mutilated or destroyed.

 

(b)           
Issuance of New Warrants. Whenever the Company is required to issue a new Warrant pursuant to the terms of this Warrant,
such new Warrant shall be of like tenor with this Warrant, and shall have an issuance date, as indicated on the face of such new
Warrant which is the same as the Issuance Date.

 

7.
          TRANSFER. This Warrant shall be binding upon the Company
and its successors and assigns, and shall inure to be the benefit of the Holder and its successors and assigns. Notwithstanding
anything to the contrary herein, the rights, interests or obligations of the Company hereunder may not be assigned, by operation
of law or otherwise, in whole or in part, by the Company without the prior signed written consent of the Holder, which consent
may be withheld at the sole discretion of the Holder (any such assignment or transfer shall be null and void if the Company does
not obtain the prior signed written consent of the Holder). This Warrant or any of the severable rights and obligations inuring
to the benefit of or to be performed by Holder hereunder may be assigned by Holder to a third party, in whole or in part, without
the need to obtain the Company’s consent thereto.

 

     6

     

    

 

8.          
NOTICES. Whenever notice is required to be given under this Warrant, unless otherwise provided herein, such notice shall
be given in accordance with the notice provisions contained in the Purchase Agreement. The Company shall provide the Holder with
prompt written notice (i) immediately upon any adjustment of the Exercise Price, setting forth in reasonable detail, the calculation
of such adjustment and (ii) at least 20 days prior to the date on which the Company closes its books or takes a record (A) with
respect to any dividend or distribution upon the shares of Common Stock, (B) with respect to any grants, issuances or sales of
any stock or other securities directly or indirectly convertible into or exercisable or exchangeable for shares of Common Stock
or other property, pro rata to the holders of shares of Common Stock or (C) for determining rights to vote with respect to any
Fundamental Transaction, dissolution or liquidation, provided in each case that such information shall be made known to the public
prior to or in conjunction with such notice being provided to the Holder.

 

9.           AMENDMENT AND WAIVER. The terms of this Warrant may be amended or waived (either generally or in a particular instance
and either retroactively or prospectively) only with the written consent of the Company and the Holder.

 

10.         GOVERNING
LAW AND VENUE. This Warrant shall be governed by and construed in accordance with the laws of the State of Delaware
without regard to principles of conflicts of laws. Any action brought by either party against the other concerning the
transactions contemplated by this Warrant shall be brought only in the state courts located in the Commonwealth of
Massachusetts or federal courts located in the Commonwealth of Massachusetts. The parties to this Warrant hereby irrevocably
waive any objection to jurisdiction and venue of any action instituted hereunder and shall not assert any defense based on
lack of jurisdiction or venue or based upon forum non conveniens. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT
MAY HAVE TO, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR UNDER ANY OTHER
TRANSACTION DOCUMENT ENTERED INTO IN CONNECTION WITH OR ARISING OUT OF THIS WARRANT OR ANY TRANSACTION CONTEMPLATED HEREBY OR
THEREBY. The prevailing party shall be entitled to recover from the other party its reasonable attorney’s fees and costs.
In the event that any provision of this Warrant or any other agreement delivered in connection herewith is invalid or
unenforceable under any applicable statute or rule of law, then such provision shall be deemed inoperative to the extent that
it may conflict therewith and shall be deemed modified to conform with such statute or rule of law. Any such provision which
may prove invalid or unenforceable under any law shall not affect the validity or enforceability of any other provision of
any agreement. Each party hereby irrevocably waives personal service of process and consents to process being served in any
suit, action or proceeding in connection with this Warrant or any other transaction document entered into in connection with
this Warrant by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to
such party at the address in effect for notices to it under the Purchase Agreement and agrees that such service shall
constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in
any way any right to serve process in any other manner permitted by law.

 

11.         ACCEPTANCE. Receipt of this Warrant by the Holder shall constitute acceptance of and agreement to all of the terms and
conditions contained herein.

 

12.         CERTAIN DEFINITIONS. For purposes of this Warrant, the following terms shall have the following meanings:

 

(a)              [Intentionally Omitted].

 

     7

     

    

(b)             
“Closing Sale Price” means, for any security as of any date, (i) the last closing trade price for such
security on the Principal Market, as reported by Quotestream or other similar quotation service provider designated by the
Holder, or, if the Principal Market begins to operate on an extended hours basis and does not designate the closing trade
price, then the last trade price of such security prior to 4:00 p.m., New York time, as reported by Quotestream or other
similar quotation service provider designated by the Holder, or (ii) if the foregoing does not apply, the last trade price of
such security in the over-the-counter market for such security as reported by Quotestream or other similar quotation service
provider designated by the Holder, or (iii) if no last trade price is reported for such security by Quotestream or other
similar quotation service provider designated by the Holder, the average of the bid and ask prices of any market makers for
such security as reported by Quotestream or other similar quotation service provider designated by the Holder. If the Closing
Sale Price cannot be calculated for a security on a particular date on any of the foregoing bases, the Closing Sale Price of
such security on such date shall be the fair market value as mutually determined by the Company and the Holder. All such
determinations to be appropriately adjusted for any stock dividend, stock split, stock combination or other similar
transaction during the applicable calculation period.

 

(c)         
    “Common Stock” means the Company’s common stock, par value $0.0001, and any other
class of securities into which such securities may hereafter be reclassified or changed.

 

(d)        
     “Common Stock Equivalents” means any securities of the Company that would entitle
the holder thereof to acquire at any time Common Stock, including without limitation any debt, preferred stock, rights,
options, warrants or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise
entitles the holder thereof to receive, Common Stock.

 

(e)              [Intentionally Omitted].

 

(f)               “Person” and “Persons” means an individual, a limited liability company, a
partnership, a joint venture, a corporation, a trust, an unincorporated organization, any other entity and any governmental
entity or any department or agency thereof.

 

(g)            “Principal Market” means the principal securities exchange or trading market where such Common Stock is listed
or quoted, including but not limited to any tier of the OTC Markets, any tier of the NASDAQ Stock Market (including NASDAQ Capital
Market), or the NYSE American, or any successor to such markets.

 

(h)            
“Market Price” means the highest traded price of the Common Stock during the one hundred and fifty Trading
Days prior to the date of the respective Exercise Notice.

 

(i)             
“Trading Day” means any day on which the Common Stock is listed or quoted on its Principal Market, provided,
however, that if the Common Stock is not then listed or quoted on any Principal Market, then any calendar day.

 

(j)              “Trigger
Date” means the date that an Event of Default (as defined in the Note) occurs under the Note.

 

*
* * * * * *

 

     8

     

    

 

IN
WITNESS WHEREOF, the Company has caused this Warrant to be duly executed as of the Issuance Date set forth above.

 

		TOUCHPOINT
GROUP HOLDINGS, INC.
	 	 
	 	 
	 	Name:
Mark White
	 	Title:
Chief Executive Officer

 

     

     

    

 

EXHIBIT
A

 

EXERCISE
NOTICE

 

(To
be executed by the registered holder to exercise this Common Stock Purchase Warrant)

 

The
Undersigned holder hereby exercises the right to purchase_______________of
the shares of Common Stock (“Warrant Shares”) of TOUCHPOINT GROUP HOLDINGS, INC., a Delaware corporation (the “Company”),
evidenced by the attached copy of the Common Stock Purchase Warrant (the “Warrant”). Capitalized terms used herein
and not otherwise defined shall have the respective meanings set forth in the Warrant.

 

		1.	Form
of Exercise Price. The Holder intends that payment of the Exercise Price shall be made as (check one):

 

☐
a cash exercise with respect to_______________Warrant Shares; or 

 ☐ by cashless exercise pursuant to the Warrant.

 

		2.	Payment
of Exercise Price. If cash exercise is selected above, the holder shall pay the applicable Aggregate Exercise Price in the
sum of $_______________to the Company in accordance with the terms of the Warrant. 

 

		3.	Delivery
of Warrant Shares. The Company shall deliver to the holder_______________Warrant Shares in accordance with the terms of the
Warrant.

           

Date: ________________________

 

		(Print
Name of Registered Holder)

 

		By:	 

		Name:	 

		Title:	 

 

     

     

    

 

EXHIBIT
B

 

ASSIGNMENT
OF WARRANT

 

(To
be signed only upon authorized transfer of the Warrant)

 

For
Value Received, the undersigned
hereby sells, assigns, and transfers unto_______________the right to purchase_______________shares of common stock of TOUCHPOINT
GROUP HOLDINGS, INC., to which the within Common Stock Purchase Warrant relates and appoints___, as attorney-in-fact, to transfer
said right on the books of TOUCHPOINT GROUP HOLDINGS, INC. with full power of substitution and re-substitution in the premises.
By accepting such transfer, the transferee has agreed to be bound in all respects by the terms and conditions of the within Warrant.

 

Dated: ___________________

 

		(Signature)
*

 

		(Name)

 

		(Address)

 

		(Social
Security or Tax Identification No.)

 

*
The signature on this Assignment of Warrant must correspond to the name as written upon the face of the Common Stock Purchase
Warrant in every particular without alteration or enlargement or any change whatsoever. When signing on behalf of a corporation,
partnership, trust or other entity, please indicate your position(s) and title(s) with such entity.Exhibit 10.26

 

 

 

Equity Acquisition Agreement

 

Party A (acquirer): ZhongYuan Nervonic Acid
Biotechnology Co.

Address: 101-3036, 1st to 3rd
floor, Building 26, No. 17, Huanke Middle Road, Tongzhou Park, Zhongguancun Science and Technology Park, Tongzhou District, Beijing

Legal representative: Chang Yu

Unified Social Credit Code: 91110112MA0057HU7E

 

Party B (transferor): Baofeng Biotechnology (Beijing) Co.

Address: Room 525, 5/F, Building 3, No. 10, Anjing Street,
Shunyi District, Beijing

Legal representative: Chang Tingting

Unified social credit code: 9111 0117 0536 2938 X8

 

Party C (target company): Dandong Baofeng Seedling Technology
Co. Address: eleven groups of Changdiancheng Village, Changdian Town, Kuandian Manchu Autonomous County, Dandong City, Liaoning Province
Legal representative: Zhai Jiangyong

Unified Social Credit Code: 91210624MA0YGFHG56

 

Party D: Yanbian Baofeng Biotechnology Co.

Address: 1177 Kailaiying Road, High-tech Industrial
Park, Dunhua City Legal representative: Miao Yuhai

Unified Social Credit Code: 91222403MA158W8D1E

 

The parties hereto, through equal
and voluntary negotiation, and in accordance with the Civil Code of the People's Republic of China, the Company Law of the People's Republic
of China and relevant regulations, enter into this contract for mutual compliance in respect of the transfer of the equity interest held
by Party B to Party A in Party C.

 

Whereas.

Party B
offered Party A 100% equity interest in Dandong Baofeng Seedling Technology Co. As Party A holds equity in Party D, Party A's purchase
in this transaction is completed by paying part of cash plus equity in Party D.

After friendly negotiation, the parties
reached the following agreement:

 

Chapter I. Subject of the transfer

Article 1 Target Company

(hereinafter referred to as "the
target company" or "the company"), was established on March 11, 2019, with a registered capital of 1 million yuan and
an actual payment of 1 million yuan; its registered address is Eleven Group of Changdian City Village, Changdian Town, Kuandian Manzu
Autonomous County, Dandong City, Liaoning Province; its unified social credit code is 91210624MA0YGFHG56.

 

Article 2 Subject of the transfer

The subject of the transfer is
all 100% equity of the target company held by Party B (including its interests and its substantial assets, the same below). After Party
A acquires the target company, the 100% equity of the target company will be evaluated and made as the paid-up capital of Yanbian Baofeng
Biotechnology Co.

 

    	 

    	 

    

Article 3 Shareholding Structure

Pre-acquisition equity structure
of the target company: 100% owned by Party B; post-acquisition equity structure of the target company: 100% owned by Party D.

Chapter II Price and taxes
and fees

Article 4 Price

A third party
appraiser [Beijing Zhenglian Asset Appraisal Co., Ltd] jointly appointed by both parties, issued the "Appraisal Report No. A1-379"
on September 6, 2022 in respect of the value of the equity interest in the Target Company, and the shareholders' equity is RMB5,000,000.00.
The parties agree that the transfer price is RMB5,000,000.00.

 

Article 5 Payment

		5.1	Payment Method

Both parties
agree that the equity transfer price shall be paid by Party A to Party B in the form of "cash + equity", of which:

One million yuan (¥1,000,000.00)
in cash.

7% equity
interest in Yanbian Baofeng Biotechnology Co., Ltd. (100% equity interest in Yanbian Baofeng Biotechnology Co., Ltd. is evaluated at RMB
56,874,300.00 (see "Evaluation Report" No. [A1-378]), which consolidates the equity value of the subject company), and the remaining
price shall be paid in the amount of four million yuan (¥4,000,000.00).

 

		5.2	Payment time

Cash payment:
Within 90 working days after the completion of the delivery of the subject equity interest, Party A shall pay Party B 1million
yuan (¥1,000,000.00).

Equity
payment: Within 5 days after the completion of the delivery of the subject equity, both parties will cooperate with each other
to handle the procedures related to the change of registration of 7% equity of Yanbian Baofeng Biotechnology Co. If it is not possible
to handle the procedures related to the change of registration of 7% equity of Yanbian Baofeng Biotechnology Co, including the exercise
of the right of pre-emption by other shareholders or Party A does not cooperate in the transfer of equity, Party B has the right to request
Party A to pay the remaining equity transfer amount of RMB 4 million in cash.

 

Article 6 Taxes and Fees

Each party to the transaction shall
pay the relevant taxes and fees thatshould be borne by itself in accordance with the Chinese
tax law.

 

Chapter 3 Transfer Base Date and Settlement
Date

Article 7 Basis date of transfer

The parties
agree that the date of the benchmark contained in the Appraisal Report made by the third-party institution jointly commissioned by the
parties shall be the benchmark date for this equity transfer.

 

    	 

    	 

    

Article 8 Date of transfer and settlement

The parties
agree that the date of the registration application for this equity transfer shall be the date of settlement of this equity transfer.

 

Chapter 4 Transfer Handover

Article 9 Legal formalities for the transfer
of shareholding

Both parties
shall complete all legal procedures such as approval and change registration related to this equity transfer and complete the delivery
within 30 working days from the date of signing this Agreement. The completion of the settlement shall enable Party A to legally
own all the equity interests of the Target Company involved in this equity transfer and to counter any objection raised by any third party
to the Subject Equity Interest or Party A.

 

Article 10 Company property handover

10.1 
Party B shall prepare a balance sheet, a detailed statement of assets, a detailed statement of debts
and liabilities as of the date of transfer, as well as an Appraisal Report issued by a third party appraiser, which shall be attached
to this Agreement after confirmation by Party A.

10.2  
Party B shall, within 30 working days from the date of signing this Agreement, complete the
property transfer procedures of the Target Company with Party A. The transferred company property includes all assets of the target company
(including but not limited to physical assets, bank accounts, seals, contracts, files, books, financial statements, rights certificates,
etc.).

10.3  
The property handover list will be signed by both parties after the handover is completed.

Article 11 Effect of property handover

After this
equity transfer, Party A legally owns all the assets of the target company according to its share of the equity ratio.

 

Chapter 5 Debt

Article 12 Debt

12.1 
Party B undertakes that Party B shall be responsible for settling and assuming full liability for
all debts incurred by the Target Company before the date of transfer and outside the schedule of debts and liabilities agreed in 10.1
of this Agreement, including any form of borrowings or external guarantees and other implicit and contingent debts. After Party B has
assumed the corresponding responsibility and voluntarily waived the recourse to the Target Company or after the Target Company has assumed
the external responsibility, Party A or the Target Company shall have the right to recourse to Party B for full liability.

 

 

    	 

    	 

    

12.2 
The claims and debts set forth in the schedule of claims and debts agreed in 10.1 of this Agreement,
as well as those arising after the transfer and settlement, shall be enjoyed and borne by the changed company.

 

Chapter 6 Party A promises and guarantees

Article 13 Representations and warranties
of Party A

		13.1	Organization

Party A is
a company legally registered, validly existing and operating in good standing under the law.

		13.2	Authorization

Party A have
full corporate power and authority to enter into and consummate the transactions contemplated by this Agreement. Party A have all necessary
corporate authority to enter into and perform this Agreement.

		13.3	Equity Payments

Party A owns
85% equity of Yanbian Baofeng Biotechnology Co., Ltd., and there is no third party interest that restricts external transfer. Party A
takes 7% equity of Yanbian Baofeng Biotechnology Co., Ltd. as the payment of the transaction price of this agreement, and should ensure
that other equity of Yanbian Baofeng Biotechnology Co., Ltd. agrees to the external transfer of Yanbian Baofeng Biotechnology Co., Ltd.
and waives the shareholders' right of first refusal.

 

Chapter 7 Party B commitment and guarantee

Article 14 Party B representations and
warranties

		14.1	Procedures and Resolutions

On the reference
date and before the settlement date, Party B has completed all relevant internal procedures required for the equity transfer.

		14.2	Ownership of Equity

Party B have
full title to the Subject Equity, free and clear of any pledges, liens, charges, encumbrances, rights of use, security interests, claims,
options and restrictions of any kind (hereinafter referred to as "Encumbrances"). There shall be no material change in any of
the rights attached to the Subject Equity Interest after the execution of this Agreement.

		14.3	Contributions

The amount
of capital contribution of the subject equity interest is one million yuan (¥1,000.000.00), and Party B has actually paid one million
yuan (¥1,000.000.00).

		14.4	Company assets

The Company
enjoys good and effective rights to tangible physical assets and intangible assets, and there is no mortgage, pledge, lien, seizure or
preservation, nor is there any dispute over ownership.

		14.5	Financial Statements

Party B shall
provide Party A with a balance sheet, a schedule of assets, a schedule of debts and liabilities as at the date of transfer and all previous
financial statements of the target company. All financial statements should be complete and correct, have been prepared in accordance
with the accounting rules applied on a continuing basis during their periods and present fairly, in all material respects, the financial
position as at the date of transfer and the results of operations and cash flows for each
period.

 

    	 

    	 

    

Chapter 8 Payment of capital

Article 15 Payment of capital contribution

The obligation
to pay the contribution of the subject equity interest, except for the part that has been actually paid by Party B as agreed in 14.3 of
this Agreement, shall be performed by Party A within the payment period stipulated in the Articles.

 

Chapter 9 Confidentiality

Article 16 Confidentiality

Each party
shall use its best efforts to maintain the confidentiality of all matters relating to the other party in all forms obtained by it as a
result of the performance of this Agreement, including but not limited to: the terms of this Agreement; the negotiation of the Agreement;
the subject matter of the Agreement; the trade secrets of each party; and the confidentiality of the contents of any business information,
materials and/or documents, including any contents of this Agreement and other matters in which the parties may cooperate. Except to the
extent that either party is required by law to disclose such confidential information to the relevant governmental authorities, or to
the direct legal and financial advisors of either party as necessary for its normal operations.

Article 17 Other obligations

The confidentiality
obligations described in this chapter shall survive the termination of this Agreement.

 

Chapter 10 Breach of contract

Article 18 Default

		18.1	Liability for breach of contract by the transferor

The transferor shall indemnify and hold
harmless the Acquirer and the Company from and against any and all losses suffered by the Acquirer arising out of or in connection with
any breach by the Grantor of any representation, warranty, undertaking or obligation under this Agreement.

		18.2	Liability for breach of contract by the acquirer

The Acquirer shall indemnify and
hold the Grantor harmless from any and all losses suffered by the Grantor arising out of or in connection with any breach by the Acquirer
of any representation, warranty, undertaking or obligation under this Agreement.

 

Chapter 11 Other

Article 19 Entry into force

This agreement will be effective
after both parties sign and seal. In order to fulfill this agreement, it is necessary for both parties to sign other agreements or legal
documents to supplement this agreement, including the simple equity transfer agreement required for industrial and commercial changes,
or the transaction documents for the equity of Yanbian Baofeng Biotechnology Co. If the content of the relevant agreement conflicts with
the content of this agreement, the content of this agreement shall prevail.

Article 20 Independence

The terms of this agreement are
independent, and if some of the terms are invalid, it does not affect the validity of the entire agreement.

Article 21 Communication

The contact information stated
in the first part of this Agreement shall be used as the address for service of all kinds of notices, agreements and other documents related
to this contract, as well as legal documents and legal papers in case of disputes regarding the contract; if one party modifies the contact
information, it shall notify the other party in writing, and the modification will be effective when received by the other party.

 

 

    	 

    	 

    

Article 22

This Agreement is signed in Beijing
on September 19, 2022, in four copies, two for each party.

 

Annexes.

		1.	Equity evaluation report of Dandong Baofeng Seedling Technology Co.

		2.	Equity evaluation report of Yanbian Baofeng Biotechnology Co.

(This page is the signature and seal page of the equity
transfer agreement of Dandong Baofeng Seedling Technology Co.)

 

Party A (acquirer).

 

 

Party B (transferor).

 

 

 

Party C (Target Company).

 

 

Party D: Yanbian Baofeng Biotechnology Co.

 

 

 

Date of Contract:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00349-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00349-of-00352.parquet"}]]